A total of 67% (4/6) of the patients had at least 1 node positive for tumor, 83% (5/6) had at least 1 estrogen receptor positive tumor; 0% (0/6) had Her-2 positive tumors, and 33% (2/6) had tumor profiles or histologies that differed between the bilateral sides. This evidence concerns the gene ESR1 and neoplasm.